Lynk Pharmaceuticals Co Ltd, a clinical-stage innovative drug development company, on Monday reported positive topline results from its Phase III clinical trial evaluating zemprocitinib in patients with moderate-to-severe atopic dermatitis (AD).

According to the company, the study met all co-primary and key secondary endpoints, with both dose groups demonstrating highly and statistically significant improvements versus placebo, together with a favourable safety and tolerability profile.

The findings represent topline data generated in accordance with the predefined statistical analysis plan. Full study data are undergoing further analysis and will be published at a future date.

A total of 356 patients participated in the multicentre study, randomised in a 1:1:1 ratio to receive zemprocitinib 12 mg, 24 mg, or placebo.